Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 86

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Chronic myeloid leukaemia

Not recruiting

Comparison of nilotinib versus imatinib treatment in newly diagnosed chronic myeloid leukemia patients to achieve treatment-free remission

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Acute myeloid leukaemia recurrent

Not recruiting

Study of Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ziftomenib
  • Sponsor:Kura Oncology Inc.

Pyruvate kinase deficiency anaemia

Not recruiting

Study on the Effectiveness and Safety of Mitapivat in Children with Pyruvate Kinase Deficiency Not Receiving Regular Blood Transfusions

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Anaemia+1

Not recruiting

Study on Canakinumab for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes or MDS/MPN

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Canakinumab
  • Sponsor:Universitaet Leipzig

Plasma cell myeloma

Not recruiting

Study of iberdomide alone or with drug combinations for patients with multiple myeloma: testing safety and effectiveness of different doses

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Celgene Corp.

Polycythaemia vera

Not recruiting

Study on the Effects of Sapablursen for Patients with Phlebotomy Dependent Polycythemia Vera

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Ionis Pharmaceuticals Inc.

Chronic granulomatous disease

Not recruiting

Study of G1XCGD Lentiviral Vector in Patients with X-Linked Chronic Granulomatous Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Autologous Cd34+ Cells Transduced With The G1Xcgd Lentiviral Vector Containing The Human Cybb Gene
  • Sponsor:Genethon

Chronic lymphocytic leukaemia

Not recruiting

Study on Obinutuzumab, Chlorambucil, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Acute myeloid leukaemia

Not recruiting

Study of Cusatuzumab and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:OncoVerity Inc.

Thrombotic thrombocytopenic purpura

Not recruiting

Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Caplacizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma

Not recruiting

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Novartis Pharma AG

Warm autoimmune haemolytic anaemia

Not recruiting

Study of ianalumab versus placebo in adults with warm autoimmune hemolytic anemia who failed previous treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.